Ipamorelin Dosage Per Day: No Trial Has Ever Tested One

Search “ipamorelin dosage per day” and you will land on a number: usually 200 to 300 micrograms, injected under the skin, once or twice a day. No published human trial has ever tested that regimen. The two studies that exist used intravenous infusion, for two different reasons, and neither was designed to answer what a self-injected daily dose does over weeks or months.

That gap matters more than it sounds. This isn’t a conservative estimate borrowed from a safer, related trial. Nobody has tested it at all.

Bottom line: the only two published human studies of ipamorelin used intravenous infusion, for a single pharmacokinetic reading and for a week-long surgical trial. Neither tested a subcutaneous daily dose for muscle, fat loss, or anti-aging, which is what most online protocols claim to be using.

What ipamorelin is, in the record that exists

Ipamorelin is a growth hormone secretagogue, a peptide that triggers the pituitary to release growth hormone by acting on a specific receptor rather than by supplying hormone directly. In ferret studies, it works through the growth hormone secretagogue receptor 1a, the same receptor ghrelin activates, and at that dose it curbed chemotherapy-induced weight loss alongside a related compound, anamorelin.^[1] That’s a result in ferrets. It says nothing about how the drug behaves once it’s injected under a person’s skin every day.

A 2026 narrative review by Dominikowski and colleagues puts ipamorelin inside a larger, blunter picture: it’s one of several growth hormone and IGF-1 axis peptides sold for self-administration where the published clinical evidence and the online dosing culture have almost nothing in common.^[2] That review is the frame for everything below.

The only trial that dosed it more than once a day

One randomized, placebo-controlled trial has tested ipamorelin against a real clinical outcome in humans. Beck and colleagues ran a multicenter, double-blind study in 114 adults recovering from open or laparoscopic bowel resection surgery, to see whether stimulating the ghrelin receptor would speed the return of gut motility after the procedure.^[3]

That is the single published example of ipamorelin given more than once in a day. Here is exactly how:

• Dose: 0.03 mg per kilogram of body weight
• Route: intravenous infusion, not subcutaneous injection
• Schedule: twice daily, from postoperative day 1 through day 7 or hospital discharge^[3]

Time to first tolerated solid meal

• Ipamorelin, 0.03 mg/kg IV twice daily: 25.3
• Placebo: 32.6

Median hours after surgery, ipamorelin versus placebo.

The result was a wash. Patients on ipamorelin tolerated a solid meal a median of 25.3 hours after surgery against 32.6 hours on placebo, a gap that did not reach statistical significance (p = 0.15).^[3] Because this was a randomized trial and not an observational chart review, that null result means something: it rules out a meaningful effect at that dose in that population, rather than simply failing to find one in messy real-world data.

This trial still doesn’t answer the “per day” question people are asking. It tested a surgical complication. Muscle gain, fat loss, and anti-aging were never the question. It ran through a hospital IV line, for at most a week, nowhere near the daily syringe and the years retail protocols assume.

The single-dose trial that set the numbers people quote

The other human study is older and narrower. Gobburu and colleagues gave eight healthy male volunteers, per dose level, a single 15-minute intravenous infusion of ipamorelin at each of five dose levels, from 4.21 up to 140.45 nmol per kilogram, to characterize how the body handles it.^[4]

40 min time to peak growth hormone release after a single IV dose PMID 10496658

Growth hormone release peaked at roughly 40 minutes after dosing and fell back to near nothing within a few hours, at every dose level tested.^[4] That is a clean, dose-proportional pharmacokinetic result. It is also, by design, a single-dose study. It cannot tell you what happens after the fortieth injection, because nobody gave a fortieth injection. A trial built to map one dose’s trajectory through the bloodstream was never built to answer whether repeating that dose daily for a year is safe or useful, and treating it as if it did is a different kind of claim than the paper makes.

Where the online “per day” number comes from

The retail protocols that quote a fixed microgram number, taken daily by syringe, are not a conservative reading of either study. They are an extrapolation across three things at once:

• Route: neither trial used a subcutaneous injection, both used intravenous infusion
• Duration: neither trial ran longer than a week, retail protocols assume months or years
• Purpose: neither trial tested a dose chosen for muscle gain, fat loss, or slowing aging

That extrapolation is not a small technicality. Route of administration changes how much of a drug the body sees. A 1992 review by Hörl on erythropoietin, a therapeutic protein of comparable size, found that subcutaneous dosing matched the effect of intravenous dosing in dialysis patients using only 30 to 50 percent of the IV maintenance dose.^[5] Same drug, same patients, and the two routes still weren’t interchangeable at equal doses. Nobody has run that comparison for ipamorelin. Anyone converting Gobburu’s IV nanomole figures into a subcutaneous microgram protocol is guessing at a conversion factor that has never been measured for this peptide.

What the trials said about safety, and what they couldn’t check

The surgical trial is also the only source of controlled human safety data. The overall rate of treatment-emergent adverse events was 87.5 percent in the ipamorelin group against 94.8 percent in the placebo group, essentially the same.^[3] That’s a genuinely reassuring number for a week of twice-daily IV dosing in a hospital.

What it doesn’t cover: a trial capped at seven days cannot speak to months or years of continuous daily injection, which is the timeline retail protocols assume.

Dominikowski and colleagues’ review of the broader growth hormone secretagogue class, ipamorelin included, flags adverse effects that neither of ipamorelin’s own trials was designed to look for: prolactin and cortisol elevation, appetite changes, and dysglycemia.^[2] Those are class-level signals rather than numbers measured specifically for ipamorelin, but the mechanism that produces them (sustained stimulation of a GH-releasing pathway) is exactly the mechanism a daily self-injection protocol is designed to trigger, repeatedly, for far longer than either published trial ran.

Ipamorelin versus CJC-1295, the usual stack

Retail sellers almost never offer ipamorelin alone. It comes bundled with CJC-1295, on the logic that the two hit different targets and so should work better together. That part is pharmacologically accurate: CJC-1295 is a long-acting analog of growth hormone releasing hormone, and Teichman and colleagues showed it prolongs GH and IGF-1 secretion in healthy adults through the GHRH receptor, distinct from the ghrelin receptor ipamorelin acts on.^[6]

What the pharmacology doesn’t supply is a trial. No published study has dosed ipamorelin and CJC-1295 together, at any ratio or schedule. The mechanistic case for stacking them is real; the clinical case is simply absent. For more on what CJC-1295’s own trial record does and doesn’t establish, see CJC-1295 and ipamorelin: real pharmacology, missing outcomes, and for how ipamorelin’s single efficacy trial compares to sermorelin’s, see Ipamorelin vs sermorelin: one has human trials, the other has a paper.

What's published versus what's sold

Route, schedule, and purpose, side by side.

What would settle this

A real answer to “what’s the daily ipamorelin dose” requires a trial nobody has run: repeated subcutaneous dosing, over weeks or months, measured against a clinical outcome or a validated biomarker, not against a 15-minute infusion’s pharmacokinetic curve. Until that trial exists, “per day” dosing for ipamorelin is a number that migrated out of a hospital IV line and into a home syringe, and nobody checked whether it still means the same thing on the way.

For the fuller picture of ipamorelin’s one efficacy trial and why it missed its own endpoint, read Ipamorelin’s only human efficacy trial missed its endpoint.

This article is for research and informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. The peptides discussed here are sold for research use only and are not for human consumption. Nothing in this article constitutes medical advice. Consult a qualified clinician before making changes to a health, training, or supplementation protocol.